Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med. 1994, 330: 1368-1375. 10.1056/NEJM199405123301908.
Article
CAS
PubMed
Google Scholar
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993, 85: 307-311. 10.1093/jnci/85.4.307.
Article
CAS
PubMed
Google Scholar
Biancone L, Calabrese E, Petruzziello C, Pallone F: Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007, 4: 78-91.
Article
CAS
PubMed
Google Scholar
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285. 10.1001/jama.295.19.2275.
Article
CAS
PubMed
Google Scholar
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46: 3151-3158. 10.1002/art.10679.
Article
CAS
PubMed
Google Scholar
Kanik KS, Cash JM: Does methotrexate increase the risk of infection or malignancy?. Rheum Dis Clin N Am. 1997, 23: 955-967. 10.1016/S0889-857X(05)70368-9.
Article
CAS
Google Scholar
Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson LT, Lindblad S: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009, 68: 648-653. 10.1136/ard.2007.085852.
Article
CAS
PubMed
Google Scholar
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1414-1420. 10.1136/ard.2004.033241.
Article
CAS
PubMed
PubMed Central
Google Scholar
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1421-1426. 10.1136/ard.2004.033993.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chakravarty EF, Michaud K, Wolfe F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005, 32: 2130-2135.
CAS
PubMed
Google Scholar
Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005, 64: 699-703. 10.1136/ard.2004.030528.
Article
CAS
PubMed
PubMed Central
Google Scholar
Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S: Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 2757-2764. 10.1002/art.22056.
Article
CAS
PubMed
Google Scholar
Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004, 50: 1740-1751. 10.1002/art.20311.
Article
CAS
PubMed
Google Scholar
Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007, 56: 2886-2895. 10.1002/art.22864.
Article
PubMed
Google Scholar
Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007, 56: 1433-1439. 10.1002/art.22579.
Article
CAS
PubMed
Google Scholar
Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P: Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 50: 1431-1439.
Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM: Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol. 2008, 35: 1704-1708.
PubMed
Google Scholar
Parikh-Patel A, White RH, Allen M, Cress R: Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009, 20: 1001-1010. 10.1007/s10552-009-9298-y.
Article
PubMed
PubMed Central
Google Scholar
Kremer J: The CORRONA database. Ann Rheum Dis. 2005, 64 (Suppl 4): v37-v41.
Google Scholar
Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36: 729-740. 10.1002/art.1780360601.
Article
CAS
PubMed
Google Scholar
Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S: Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007, 18: 561-569. 10.1007/s10552-007-0131-1.
Article
PubMed
Google Scholar
Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM: Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009, 15: 659-668.
PubMed
Google Scholar
Curtis JR, Jain A, Askling J, Bridges SL, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J: A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010, 40: 2-14 e11. 10.1016/j.semarthrit.2010.03.003.
Article
PubMed
PubMed Central
Google Scholar
Kremer JM, Greenberg J: Interpreting registry-derived drug studies: does societal context matter?. Arthritis Rheum. 2009, 60: 3155-3157. 10.1002/art.24880.
Article
PubMed
Google Scholar